<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285554</url>
  </required_header>
  <id_info>
    <org_study_id>932</org_study_id>
    <nct_id>NCT04285554</nct_id>
  </id_info>
  <brief_title>Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects</brief_title>
  <acronym>DeLIVER</acronym>
  <official_title>A Prospective, Single-Arm, Multi-Center Study of the Metavention Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metavention</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metavention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this early feasibility study is to evaluate the safety and performance of
      intravascular hepatic denervation using the Metavention Integrated Radio Frequency
      Denervation System (iRF System) to improve glycemic control in type 2 diabetes subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is a prospective, single-arm, multi-center, non-randomized trial</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Serious Adverse Device Effects</measure>
    <time_frame>Index Procedure through 90 days</time_frame>
    <description>The incidence rate of serious adverse device effects (SADEs) from time of Index Procedure through 90 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control: HbA1c</measure>
    <time_frame>30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in glycemic control as indicated by HbA1c blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control - FPG</measure>
    <time_frame>30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in glycemic control as indicated by fasting plasma glucose blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control - Insulin</measure>
    <time_frame>30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in glycemic control as indicated by insulin blood test during Mixed Meal Tolerance Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control - C-peptide</measure>
    <time_frame>30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in glycemic control as indicated by c-peptide blood test during Mixed Meal Tolerance Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office blood pressure</measure>
    <time_frame>30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in office blood pressure: systolic and diastolic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver steatosis</measure>
    <time_frame>90 and 365 days</time_frame>
    <description>Change from baseline in liver steatosis from baseline as measured using MRI-PDFF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event rate 365 days</measure>
    <time_frame>Consent through 365 days</time_frame>
    <description>Adverse Event rate: Summary of all reported adverse events during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Hepatic Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iRF System Hepatic Denervation</intervention_name>
    <description>The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).</description>
    <arm_group_label>Hepatic Denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥22 and ≤65 years old

          2. Type 2 Diabetes diagnosis meeting the following criteria:

               1. Hb1Ac &gt; 7.0% and ≤ 9.0% (53 mmol/mol - 75 mmol/mol), AND

               2. On two OAD medications; one at the highest tolerated dose with no changes in
                  medication dose in the 12 weeks prior to the first screening visit

          3. Waist circumference ≥102 cm (male) and ≥88cm (female)

          4. Diagnosis of hypertension: SBP ≥140mmHg OR SBP ≥130mmHg on hypertension medications (2
             or less)

          5. MRI-PDFF ≥10% indicating non-alcoholic fatty liver disease (NAFLD)

          6. Documented status of stable lifestyle modifications

          7. Women of childbearing potential (WOCBP) must be using at least one acceptable method
             of contraception throughout the study

        Exclusion Criteria:

          1. BMI &gt;40 kg/m2

          2. Diagnosis of type 1 diabetes

          3. Current or previous use of injectable diabetes medications (e.g., insulin and GLP-1RA)

          4. Current use of &gt;2 hypertension medications

          5. Two or more self-reported or documented severe hypoglycemia events (severe
             hypoglycemia event defined as: hypoglycemia associated with severe cognitive
             impairment requiring external assistance for recovery) in the 180 days prior to Index
             Procedure

          6. One or more documented hyperglycemia episodes requiring hospitalization in the
             180-days prior to Index Procedure

          7. During medication run in period, uncontrolled hyperglycemia noted by a fasting glucose
             value of &gt;270mg/dL or &gt;360mg/dL at any point that is then confirmed by a second
             measurement (not on the same day)

          8. A history of bariatric surgery, renal denervation, baroreflex activation therapy, or
             liver transplant, or these procedures are planned in the 365 days following Index
             Procedure

          9. Any surgical procedure within 30 days prior to Index Procedure

         10. History of gallstones without a cholecystectomy being performed or current gallstones
             (Note: subjects who have had a cholecystectomy are not excluded)

         11. Previous hepatobiliary surgery/intervention that in the opinion of the investigator
             could preclude the ability to perform denervation of the common hepatic artery

         12. Currently taking the following medications within 90 days prior to screening and/or
             there is a need or anticipated need for these medications during the study:

               1. Systemic Corticosteroids

               2. Anticonvulsants

               3. Centrally acting sympatholytics

         13. Use of anticoagulation therapy which cannot be discontinued from 7 days before to 14
             days after the Index Procedure

         14. Any other condition(s) that would compromise the safety of the Subject or compromise
             study quality as judged by the Investigator

         15. eGFR &lt;60 mL/min/1.73 m2

         16. History or diagnosis of proliferative retinopathy or advanced autonomic neuropathy
             (e.g., orthostatic hypotension attributable to autonomic neuropathy, a diagnosis of
             gastroparesis, or a clinical history strongly suggestive of delayed gastric emptying)

         17. Unstable cardiovascular disease, myocardial infarction, unstable angina, widespread
             atherosclerosis with documented intravascular thrombosis or unstable plaques

         18. Documented history or concurrent signs of significant thyroid disease NOTE: If a
             subject is on chronic thyroid drug treatment, and has a serum TSH test result in
             normal range at Baseline they may enter study

         19. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet
             count &lt;100,000/microliter, or documented coagulopathy

         20. Significant alcohol consumption, defined as more than 2 drink units per day
             (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men,
             or inability to reliably quantify alcohol intake

         21. Active substance abuse, based on Investigator judgment, including inhaled or injected
             drugs, within 1 year prior to the initial screening

         22. Significant weight loss within the last 6 months (e.g., &gt;10% total body weight loss)

         23. Hepatic decompensation defined as the presence of any of the following:

               1. Serum albumin less than 3.5 g/dL

               2. International normalized ratio (INR) greater than 1.4 (unless due to therapeutic
                  anticoagulants)

               3. Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome

               4. History of esophageal varices, ascites, or hepatic encephalopathy

         24. ALT or AST greater than 200 U/L

         25. Diagnosis of liver cirrhosis

         26. Chronic liver or biliary disease of the following etiology:

               1. History or diagnosis of Hepatitis B

               2. History or diagnosis of Hepatitis C

               3. History or diagnosis of current active autoimmune hepatitis

               4. History or diagnosis of primary biliary cholangitis (PBC)

               5. History or diagnosis of primary sclerosing cholangitis

               6. History or diagnosis of Wilson's disease

               7. History or diagnosis of alpha-1-antitrypsin deficiency

               8. History or diagnosis of hemochromatosis

               9. History or evidence of drug-induced liver disease, as defined on the basis of
                  typical exposure and history

              10. Known bile duct obstruction

              11. Suspected or proven liver cancer

         27. History of acute or chronic pancreatitis

         28. Subjects unable to undergo MRI-PDFF or CT for any reason

         29. Currently enrolled in any other investigational trial

         30. History of an acute neurologic event including epilepsy, seizures, stroke, and
             transient ischemic attack.

         31. Iliac/femoral artery stenosis precluding insertion of the catheter

         32. Human immunodeficiency virus (HIV)

         33. Subjects with a history of adverse reaction to heparin or heparin induced
             thrombocytopenia (HIT)

         34. Subjects with conditions that can affect RBC turnover, those who have received a blood
             transfusion in the past 90 days, or expect to have an elective procedure during the
             course of the study that may require blood transfusion

         35. Not a candidate for surgery or general anesthesia

         36. Unwilling to comply with study requirements, including medication run-in, SMBG,
             patient diary and follow-up visits

         37. Subjects with implantable pacemakers, implantable cardiac defibrillators or
             implantable neurostimulators Anatomic Exclusions from CT Angiogram

         38. Replaced or accessory LHA or RHA determined on CT angiogram.

         39. Vessel tortuosity or variant vascular anatomy that could preclude the access or
             maneuvering of the device from the femoral artery to the target location

         40. Evidence of CHA and/or portal vein intraluminal thrombus

         41. CHA vessel diameter &lt;4.0mm or &gt;7.0mm

         42. CHA diameter stenosis &gt;30%

         43. CHA vessel length &lt;20mm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Megan Brandt</last_name>
    <phone>+1-612-814-8204</phone>
    <email>mbrandt@metavention.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiology, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan DeRamus, RN, Clinical Research Director</last_name>
      <phone>205-949-5275</phone>
      <email>sderamus@cardiologypc.com</email>
    </contact>
    <investigator>
      <last_name>Farrell Mendelsohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hillary Ta</last_name>
      <phone>650-721-0372</phone>
      <email>hta@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Perlas, RN</last_name>
      <phone>650-723-2094</phone>
      <email>mperlas@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bryant Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David P Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina Basina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>407-303-7100</phone>
      <email>Fh.tri.recruitment@adventhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Kory Grench</last_name>
      <phone>407-303-7100</phone>
      <email>kory.grench@adventhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Pratley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rohit Bhatheja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Richmond, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Thethi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Education &amp; Research Cooperative (PERC)</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Sanders</last_name>
      <phone>217-546-2064</phone>
      <email>MSanders@prairieresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Gwen Sondgeroth, RN</last_name>
      <phone>217-546-2064</phone>
      <email>Gsondgeroth@prairieresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Krishna Rocha-Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Widicus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metropolitan Cardiology Consultants</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brittany Renier, RN</last_name>
      <phone>763-427-9980</phone>
    </contact>
    <contact_backup>
      <last_name>Jeff Chambers, MD</last_name>
      <phone>763-427-9980</phone>
    </contact_backup>
    <investigator>
      <last_name>Jeff Chambers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Hypertension</keyword>
  <keyword>High Blood Pressure</keyword>
  <keyword>Glycemic Control</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Denervation</keyword>
  <keyword>Sympathetic Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

